SCHEMBL3093039

SCHEMBL3093039

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2O)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
KAT6A Q92794 1/20 0.48
LARS1 Q9P2J5 1/20 0.43
ALOX15 P16050 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
F2 P00734 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.39
PLG P00747 2/20 0.39
KLK1 P06870 2/20 0.39
KLK6 Q92876 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093284 0.91 KAT6A (0.49) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3100534 0.91 KDR (0.43) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL15000205 0.90 MEN1 (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3096098 0.90 LARS1 (0.45) MEN1KMT2ANPC1KAT6ALARS1
SCHEMBL3096503 0.90 LARS1 (0.45) MEN1KMT2ANPC1KAT6ALARS1
SCHEMBL3100518 0.90 NPC1 (0.51) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3086202 0.90 SMO (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3101165 0.90 NPC1 (0.51) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3097268 0.90 LARS1 (0.42) MEN1KMT2ANPC1KAT6ALARS1
SCHEMBL3102970 0.89 MMP9 (0.46) MEN1KMT2ANPC1RAB9AKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MEN1 2509/4885KMT2A 1948/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.